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Abstract
Community-acquired pneumonia is a common and serious disease, with high rates of morbidity and mortality.
Management and treatment of community-acquired pneumonia are described in three main documents: the 2007
American Thoracic Society guidelines, the 2011 European Respiratory Society guidelines, and the 2009 British
Thoracic Society guidelines, updated by the NICE in 2015. Despite the validity of current guidelines in improving
prognosis and management of patients with community-acquired pneumonia, not all recommendations have high
levels of evidence and there are still some controversial issues. In particular, there are some areas of low evidence
such as the efficacy of an antibiotic molecule or scheme in patients with same risk factors; duration of antibiotic
treatment, supportive therapy for acute respiratory failure and immunomodulation molecules.
This review will summarize the main recommendations with high level of evidence and discuss the recommendations
with lower evidence, analyzing the studies published after the guidelines’ release.
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Background
Community-acquired pneumonia (CAP) is a common and
serious disease, with high rates of morbidity and mortality.
It represents the third leading cause of death worldwide
and the sixth in United States of America (USA), affecting
more than 4 million adults. CAP is accountable for ap-
proximately 1 million hospital admissions with a highly
significant impact on health care resources [1]; in the USA
the costs amount to more than $20 billion in direct health
care annually [2].
Management and treatment of CAP are described in
three main documents: the 2007 American Thoracic Soci-
ety (ATS) guidelines, the 2011 European Respiratory
Society (ERS) guidelines, and the 2009 British Thoracic
Society (BTS) guidelines, updated by the NICE in 2015
[3–5]. The efficacy of these guidelines in improving differ-
ent outcomes, such as reduction of unnecessary hospitali-
zations and readmissions, length of hospital stay, cost and
mortality, has been established in different contests [6, 7].
Despite the validity of current guidelines in improving
prognosis and management of patients with CAP, not all
recommendations have high levels of evidence and there
are still some controversial issues. This review will
summarize the main recommendations with high level
of evidence shared by the main guidelines, and discuss
the recommendations with lower evidence, analyzing the
studies published after the guidelines’ release.
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Summary of strong recommendations for the
treatment of CAP
Below are summarized the recommendations with
stronger evidence divided into three main categories:
antibiotic therapy, supportive treatment and manage-
ment of immunomodulation-inflammation response.
1) Antibiotic therapy:
Choice of antibiotic
The choice of empirical treatment should
ensure a spectrum of action with a high
probability of covering the germs responsible for
pneumonia, and at the same time avoid
antibiotics overuse.
The recommendations for antibiotic choice are
different based on the severity of the disease,
distinguishing an antibiotic scheme for
outpatients, for in-patients and for patients hospi-
talized in intensive care units (ICU). The recom-
mendations in the various guidelines have a
sufficient degree of overlap, although the reported
levels of evidence are different (Table 1), highlight-
ing the need for further studies in this area [3–5].
Route of administration
Antibiotics should be administered by oral route
for outpatients. For inpatients, endo-venous treat-
ment should be switched to oral administration as
clinical stability is obtained [3–5].
Monitoring
Monitoring of pneumonia should be conducted
using simple clinical criteria (fever, respiratory
rate, hemodynamic parameters) and biomarkers of
inflammation such as C-reactive protein (CRP) or
procalcitonin (PCT) [3].
These parameters are fundamental to define
clinical stability and, therefore, guide switch to
oral antibiotic therapy.
Starting treatment
Antibiotic treatment should be started within 1 h
after the diagnosis of pneumonia in case of septic
shock, because this reduces mortality, while the
recommendations in the other categories of
patients have a low level of evidence [3, 4].
Duration of the treatment
There are not specific recommendations regarding
the proper duration of antibiotic treatment [3–5].
2) Supportive treatment:
Supportive care is essential to ensure stability of vital
functions altered by the acute condition and to
prevent complications related to loss of function.
Main recommendations from different guideline are
summarized in Table 2.
3) Management of immunomodulation-inflammation
response
There are strong recommendations against routine
use of steroids, even in severe CAP, or the use of
colony stimulating granulocyte [3, 5]. Despite these
recommendations, many recently published studies
showed great interest on this subject [8–10].
Recommendations with lower evidence and
analysis of studies published after guideline
release
1) Antibiotic Therapy
Choice of antibiotic
The choice of the empirical therapy scheme
should be the best possible for the treatment of
pneumonia and individualized for each patient, in
terms of efficacy of the antibiotic (single agent or
combination treatment) and ability to detect the
presence of germs with particular profiles of
resistance.
Recommendations for the choice of antibiotics
differ among guidelines and among the various
sub classes of patients: outpatients, inpatients,
intensive care unit (ICU)-patients. In particular,
the body of evidence indicating the superiority of
β-lactam and combination of β-lactam with a
macrolide are based on cohort studies and obser-
vational studies [11], but studies with more ad-
equate design are needed.
Two randomized controlled trials (RCTs) have
been recently published addressing this topic [12,
13]. The first evaluates the equivalence of efficacy
of beta-lactam antibiotic alone vs beta lactam plus
macrolide or vs levofloxacin alone in the treatment
of hospitalized CAP. Results showed the non-
inferiority of beta lactam vs the actual recom-
mended scheme. Nevertheless, this study is un-
likely to impact on clinical practice because a great
number of recruited patients did not meet criteria
for hospitalization, and guidelines already suggest
the use of beta lactam monotherapy for mild and
moderate CAP.
The second RCT included moderate and severe
patients, and again compared beta-lactam mono-
therapy with combination treatment [13]. Results
showed a trend toward superiority of the combin-
ation of beta-lactam and macrolide compared to
beta-lactam monotherapy in achieving clinical sta-
bility. A greater effect was found in patients with
more severe forms of pneumonia and in patients
whose infection was sustained by “atypical” patho-
gens. The results of the study are not conclusive
but seem to confirm the clinical approach recom-
mended by the guidelines [12, 13].
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A systematic review evaluated studies that
compared the efficacy of treatment with
fluoroquinolones versus combination therapy
with macrolides and beta-lactams in adult pa-
tients hospitalized with CAP. Seventeen studies
were included (16,684 patients) but no random-
ized controlled study was identified and the
body of evidence had very low quality. There-
fore, recommendations cannot be made in
favor or against the two different regimens of
treatment [14].
New antibiotics could increase the efficacy of
pneumonia treatment in comparison with the
molecules and combinations available today. One
of these is Solitromicine, a fourth-generation
macrolide, that demonstrated non-inferiority com-
pared to Moxifloxacin in a phase III study that en-
rolled patients from North and Latin America,
Europe and South Africa, suggesting a possible
role of new macrolide antibiotics in the treatment
of CAP [15].
The presence of multi drug resistant pathogens
among patients with CAP is concerning, as it
represents a possible cause of treatment failure
and worse prognosis.
To address this topic the definition of health-care
associated pneumonia (HCAP) was developed in
2005. The proposed definitions were then found not
to be fully applicable due to a lack of scientific evi-
dence and for the tendency towards large-spectrum
antibiotic overuse [16]. Models based on clinical risk
factors and scores were subsequently proposed to
identify patients with CAP but at risk for infection
with multidrug resistance germs [17–21].
Models to detect multidrug resistance bacteria
have been proposed by the studies of Shorr and
Aliberti [17, 18]. Shorr score is thus composed: 4
points if recent hospitalization, 3 points if
presenting from long term facilities, 2 points if on
hemodyalisis, 1 point if admitted to the ICU
within 24 h of evaluation in the emergency
department. The Aliberti score attributes 5 points
Table 2 Supportive care for patients with pneumonia
Respiratory failure Mild Oxygen therapy
Severe Invasive ventilation with protective low tidal volume (6 ml/kg) if bilateral
infiltrate or ARDS
Severe NIV contraindicated in the majority could be used as personized option
Prevention of DVT and pulmonary
throboembolism
In patients with reduced
mobility
LMWH or heparin
Prevention of disabilities Early mobilization from the day after the onset of the symptoms
ARDS Acute Respiratory Distress Syndrome, NIV Non Invasive Ventilation, LMWE Low Molecular Weight Heparin
Table 1 Empirical antibiotic therapy scheme for Community Acquired Pneumonia in the main international guidelines
Outpatients Inpatients ICU-patients
ICDS/ATS
2007
Guideline
Previously
Healthy
Macrolide
Doxycycline
Respiratory Fluoroquinolones Or β-
Lactam plus macrolide
No
pseudomonas
risk factors
Β-Lactam (Cefotaxime, ceftriaxone or
ampicillin-sulbactam) plus azithromycin or Re-
spiratory fluoroquinolones.
For penicillin-allergic patients, a respiratory
fluoroquinolones and aztreonam.
Comorbidities Fluoroquinolones
or βLactam plus
macrolide
Risk factor for
P aeruginosa
Antipneumococcal, antipseudomonal β lactam
(piperacillin-tazobactam, cefepime, imipenem
or meropenem) plus ciprofloxacin or
levofloxacin (750 mg) Or plus aminoglycoside
and azithroycin
BTS 2009
(Update
NICE
2015)
Amoxicillin 500 mg TID
OR
Clarithromycin (Alternative if
Hypersensitive)
Amoxicillin and Macrolide OR
Macrolide (Alternative if
Hypersensitive) OR Doxycicline OR
Levofloxacin or moxifloxacin
Broad spectrum β lactamase antibiotic plus macrolide
Second or third generation cephalosporin, if hypersensitivity to
β lactam, plus clarithromycin
ERS/
ESCMI
2011
Amoxicillin or Tetracycline
Tetracycline or macrolide
Alternative
Levofloxacin or moxifloxacin
(Alternative if hypersensitivity in
countries with high incidence of
macrolide resistant
pneumococcus)
Aminopenicillin plus macrolide
Aminopenicillin/β lactamase
inhibitor plus macrolide
Non antipseudomonas
cephalosporin plus macrolide
Levofloxacin
Moxifloxacin
Penicillin G plus macrolide
No
pseudomonas
risk factors
Non antipseudomonal cephalosporin III plus
macrolide Or Moxifloxacine or levofloxacin
plus non antipseudomonas cephalosporin III
Risk factor for
P aeruginosa
Antipseudomonal cephalosporin or
acylureidopenicillin/βlactamase inhibitor or
CarbapenemPlus Ciprofloxacin or Plus
Macrolide plus Aminoglycoside
ICDS, Infectious Diseases Society of America; ATS American Thoracic Society, BTS British Thoracic Society, NICE National Institute for Health and Care Excellence,
ERS European Respiratory Society, ESCMI European Society for Clinical Microbiology and Infectious Disease
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in presence of chronic renal failure, 4 points if
hospitalization for more than 2 days in the
preceding 90 days, 3 points if resident in a nursing
home or extended care facility, 0.5 points if one of
the following are present: cerebrovascular disease,
diabetes, chronic obstructive pulmonary disease
(COPD), antimicrobial therapy in the preceding
90 days, immunosuppression, home care wound
care, home infusion therapy.
These models showed a higher efficacy in identify
patients with CAP due to multidrug resistant germs
compared with the HCAP definition [17, 18].
The classic risk factors for Pseudomonas
aeruginosa infections (lung structural
abnormalities, recent use of antibiotics or recent
hospitalization and use of corticosteroids) do not
intercept all patients with CAP due to
Pseudomonas aeruginosa as showed by a
population-based study conducted in the US in
which even patients with dementia and cerebro-
vascular disease had a higher incidence of this
pathogen [22]. The use of empirical antibiotics ac-
tive also against Pseudomonas aeruginosa in pa-
tients who are then found infected with this germ,
improved the prognosis regardless of the presence
or absence of risk factors [22] indicating that it is
the presence of the pathogen and no other factor
that affects the prognosis of these patients.
Methicillin-resistant Staphylococcus aureus
(MRSA) has recently been found to be a frequent
cause of CAP [23].
This concern has led to the development of an
international, multicenter, point-prevalence study
to determine specific risk factors associated with
MRSA infection in hospitalised patients with com-
munity acquired pneumonia (GLIMP study) [24].
The GLIMP study involved 222 hospitals in 54
countries across 6 continents. The global incidence
of MRSA in CAP was about 3%, but with signifi-
cant regional differences: incidence was >10% in
Eastern Europe, China and Brazil, 10.5% in the
United States, Northern Europe and Australia, 1–
5% in Southern Europe and France. The main risk
factors identified by the study were previous
MRSA infection, recurring skin infections, and the
presence of severe pneumonia. [24]
The different geographical distribution of resistant
bacterial strains must be taken into account when
we treat patients empirically. For example, an
observational study conducted in Japan showed a
greater efficacy of moxifloxacin compared to
levofloxacin or Beta lactam in patients with CAP
not requiring hospitalization [25]. The result is
especially interesting for the Eastern regions of the
world, but it is not generalizable and differs from
that reported by other similar studies conducted
in regions with lower levels of resistance to
levofloxacin [26].
The availability of accurate information about risk
factors for infection by specific pathogens and
local peculiarity are important to implement local
guidelines, in order to change clinical practice and
in particular the choice of empirical antibiotics for
CAP [27]. An observational study conducted after
the introduction of internal guidelines that limited
the use of fluoroquinolones and third-generation
cephalosporins as empirical therapy for pneumo-
nia, found a decrease in length of stay and hospital
mortality, [28] probably due to a better allocation
of antibiotic therapy and clinical resources.
Starting treatment
The recommendation to start antibiotics within
4 h from the diagnosis of pneumonia in the
absence of septic shock had low level of evidence;
nevertheless a study on the implementation of the
bundles of pneumonia management revealed that
early administration of antibiotics is one of the
more consistent interventions leading to reduced
30-day mortality [30-day mortality IP 22/250
(8.8%) vs. 253/1862 (13.6%), adjusted OR 0.59, 95%
CI 0.95 to 0.37, p = 0.030] [29], confirming the
need of an early start of adequate antibiotic treat-
ment for pneumonia.
Duration of antibiotic therapy
The majority of available studies that give precise
recommendations about the proper duration of
antibiotic therapy for pneumonia are applicable in
the management of severe pneumonia, especially
for patients treated in the Intensive Care Unit
(ICU). In this context, the duration of antibiotic
treatment can be guided by the trend of
procalcitonin levels; antibiotic could be
interrupted when PCT levels reach 0.1 ng/ml [30].
Despite this evidence, there is tendency towards
protracted empirical antibiotic therapy in the
absence of justifiable criteria, even in the
management of ICU patients [31]. This finding
indicates how strong is the feeling of security that
prolonging antibiotic treatment induces in
physicians, as opposed to not prescribing or
interrupting antibiotic therapy in the absence of a
clear need for these drugs.
This feeling is even greater in the setting of non-
severe pneumonia where consistent data regarding
adequate duration of antibiotic therapy are lacking
and proper studies are needed. In this contest, a
RCT conducted in Spain tried to assess the differ-
ence in the effectiveness of short antibiotic
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treatment (outstanding Antibiotic 48 h after reach-
ing clinical stability) vs. a traditional treatment
based on individual medical judgment. The study
has the merit of being one of the first prospective
studies on this subject to be completed and sus-
tained the use of short course antibiotic therapy,
based on equal efficiency but lower rate of side ef-
fects or development of bacterial resistance. Un-
fortunately, the results presented are not
applicable in clinical practice yet because of some
methodological bias, in particular the choice of a
clear primary outcome, the calculation of sample
size, as well as the low generalizability due to the
extensive use of fluoroquinolones (80% of cases)
[32].
Another recent multicenter, non-inferiority, ran-
domized, controlled trial of hospitalized adult pa-
tients with CAP was conducted to evaluate
antibiotic duration [33]. Patients who reached clin-
ical stability within 5 days after hospitalization
were randomized to a standard vs. individualized
antibiotic duration. Unfortunately, the monitoring
and safety board committee decided to interrupt
the trial because a higher rate of early failure at
30 days was found at the intention-to-treat ana-
lysis in patients with de-escalation of therapy
based on clinical stability in comparison to the
standard group. In addition, authors found proto-
col violation in 17% of cases, causing a significant
difference between intention-to-treat and per
protocol analysis. These findings suggest that phy-
sicians are more confident in prolonging antibiotic
therapy even when clinical stability is reached [31].
Specifically, the authors discussed that time to
clinical stability may not be the correct criterion
to identify patients who would benefit from indi-
vidualized therapy as no differences were found
between patients who did or did not undergo
protocol violation. Moreover, even the 5 days cut
off may be incorrect, as the majority of protocol
violations occurred when clinical stability was
reached between day 4 and day 5, in comparison
to patients reaching clinical stability on day 3. The
authors underlined that the 3 days cut off may be
used for further trials. Finally, 20% of patients re-
fused to participate for concerns regarding discon-
tinuing antibiotic therapy, and only 18% of patients
were randomized, limiting the generalizability of
the results.
2) Supportive treatment
Adequacy of empirical antibiotic therapy is
essential for a good outcome [34], but it is not
sufficient in all cases. In fact, despite an adequate
antimicrobial treatment, patients with at least two
of the following risk factors 1) hypoalbuminemia
(<30 mg / L), 2) need for hospitalization, 3)
arterial blood pH <7.35, 4) tachypnea
(FR > 30 bpm) and 5) high levels of urea, have a
significantly higher 30-day mortality. The early
identification of patients who might benefit from
an additional supportive therapy is important for
a better management and hopefully a better prog-
nosis [35].
Serum PCT concentration is associated with the risk
of requiring invasive ventilation or vasopressors
support in adults hospitalized with CAP. The risk
rises by 1–2% for each 1 ng/mL increase in PCT
when PCT level are less than 10 ng/ml, over this
limit the risk remains relatively constant at 22.4%.
[36] This finding could be useful when evaluating
ICU admission in severe CAP.
Respiratory failure
The most frequently required supportive care
occurs in patients with respiratory failure.
The studies conducted after the guidelines’
publication evaluated the use of non-invasive re-
spiratory support methods, particularly the use of
Helmet Continuous Positive Airway Pressure
(CPAP), Non-invasive ventilation (NIV) and high
flow nasal cannula oxygen therapy (HFNCO) in
the management of severe acute respiratory failure
due to pneumonia.
The use of Helmet-CPAP reduced the risk of
meeting predictive criteria for intubation in com-
parison to oxygen therapy in severe acute respira-
tory failure due to pneumonia [37] providing a
possible tool to avoid treatment with invasive ven-
tilation in these patients.
Application of NIV in acute respiratory failure due
to CAP is more controversial and showed a
possible increase in mortality in patients with de
novo-respiratory failure, probably due to a delay in
intubation caused by a prolonged use of NIV.
Conversely, in patients with a previous episode
of respiratory insufficiency or with acute on
chronic respiratory failure, NIV seems to be a
safer option [38].
The use of HFNC in acute respiratory failure does
not seem to be superior to traditional oxygen
delivery systems or to NIV in reducing the need
for intubation. However, in a post hoc analysis,
patients with more severe respiratory failure
(PaO2/FiO2 < 200) had lower risk of intubation if
treated with HFNC compared to traditional
oxygen or NIV, indicating a possible role of this
technique in this type of patients [39]. Further
studies are needed to identify the precise
indication of HFNC in CAP.
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Another study gave similar preliminary data about
the success of HFNC using the ROX index
(Respiratory rate-oxygenation), the ratio of SpO2/
FiO2 to Respiratory rate [40]. Patients with an
index greater than 4.88 after 12 h of treatment
with HFNC had a significantly different percentage
of intubation in comparison to patients with a
lower ROX index. Despite some limits, this study
identifies one of the first tools specifically applic-
able to the HFNC technique in the treatment of
acute respiratory failure in CAP [40].
3) Management of immunomodulation-
inflammation response
There has been little progress in the management
of CAP since the widespread introduction of
antibiotics in the 1950s. Among other causes, it
seems that in some patients treatment failure
depends on an excessive inflammatory response.
On the basis of this hypothesis, different agents
with an immunomodulatory activity had been
tested in the treatment of CAP.
Macrolides
Macrolides are used in various fields as
immunomodulants, particularly in the treatment
of chronic infection with Pseudomonas aeruginosa
in patients with cystic fibrosis [41] and to a lesser
extent in patients with bronchiectasis not caused
by cystic fibrosis (NCFBC) [42].
A retrospective study conducted in patients with
pneumonia caused by Pseudomonas aeruginosa
showed no evidence of a clear benefit in terms of
mortality at 30 days in patients treated with
macrolides, suggesting that the immunomodulatory
role of macrolides in this type of conditions did not
modify patients prognosis [43]. However, due to the
retrospective design of the study, it is not possible to
draw definitive conclusions about the use of
macrolides as immunomodulants in the treatment
of CAP due to Pseudomonas aeruginosa. Future
prospective randomized studies are needed to better
understand the usefulness of macrolides in this
contest.
Immunoglobulins
The use of immunoglobulins in patients suffering
from severe pneumonia is not routinely
recommended. The Japanese guidelines indicate
immunoglobulins as a possible treatment with a
low level of evidence [44]. Nevertheless, a cohort
study that involved ICUs in the entire country of
Japan provided no new evidence in favor of
using immunoglobulins in severe CAP [45]. The
use of immunoglobulins in severe CAP is,
therefore, not applicable in absence of specific
immune response deficits.
Statins
There are several observational studies that seem
to indicate a role of statins in improving the
prognosis of patients with pneumonia, but at the
moment the possible mechanisms of action are
not known and it is not possible to affirm their
clinical utility with certainty [46]. A study
specifically evaluating neutrophil activation by
statins during sepsis will soon be conducted; this
study could provide data about their real
mechanism of action in infections, thus giving the
rational basis for future clinical studies [47].
Corticosteroids
A series of scientific studies published in the last
10 years and two recent meta analyses showed
that the use of corticosteroids in pneumonia may
reduce the risk of acute respiratory distress
syndrome (ARDS), length of stay (LOS), length of
stay in the ICU, risk of clinical failure [8], duration
of antibiotic therapy and time to clinical stability
[9].
On the contrary, in other studies patients treated
with adjunctive corticosteroid therapy had a
higher incidence of hyperglycemia requiring
insulin therapy and there was not clear evidence of
a reduction in mortality [10, 48].
There are many unanswered questions on this
topic: which type of corticosteroid should be used?
Could there be a rebound in the inflammatory
response when treatment is stopped? Do all
patients benefit from steroid treatment? Which is
the better route of administration?
Some of these questions have only partially been
answered. From a post hoc analysis, it seems that
patients with pneumococcal pneumonia did not
benefit from corticosteroids, in terms of reduction
of antibiotic treatment duration [49]. This could
pose a limit to the indication of steroid treatment
in CAP, as S pneumoniae is the most frequent
pathogen causing pneumonia in the community.
Corticosteroids may be useful in certain subgroups
of patients with pneumonia, but at the moment
the use of corticosteroids in pneumonia does not
provide better results than the proper application
of the guideline recommendations [50].
Pidotimod
Among immunomodulators, Pidotimod is a
synthetic dipeptide molecule endowed with
immunomodulatory activity that affects both
innate and adaptive immune responses. Previous
positive effects on inflammation were obtained in
in vitro studies [51, 52]; and subsequently in in
vivo studies, where the drug reduced the incidence
of upper and lower airways symptoms in children
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[53], and augmented the influenza specific
immune responses in patients with Down
syndrome who underwent vaccination [54]. Lastly,
a recent multicenter, interventional, prospective
study was conducted on adult patients hospitalized
with community acquired pneumonia [55].
Patients were randomized to receive either
levofloxacin 500 mg bis in die, alone or
levofloxacin plus PDT (800 mg, 2 daily doses).
Supplemental therapy with pidotimod resulted in
an increased antimicrobial and
immunomodulatory effect and in a reduction of
inflammatory chemokines. Thus, authors suggest
that adjunctive therapy with pidotimod could have
a positive effect on innate immunity among
patients with CAP, but the use of
immunomodulators are not recommendable in
clinical practice yet.
Expert opinion
Treatment of CAP is well described by the guidelines
now available and its efficacy is demonstrated. However,
there are some areas of low evidence, in particular the
efficacy of single agent over combination treatment in
patients with similar risk factors; duration of antibiotic
treatment and supportive treatment. Studies published
after the guidelines are interesting but not sufficiently
conclusive to modify the above recommendations.
Undoubtedly, further studies are needed to address the
duration of therapy issue, in order to acknowledge if an
earlier suspension of antimicrobial treatment is viable to
all hospitalized patients with CAP and avoid antibiotic
overuse. Future studies need to be less strict in selecting
criteria, including a more heterogeneous population, re-
sembling real life.
Multi drug resistant organisms (MDRO) are nowadays
a challenge for all clinicians, and respiratory tract infec-
tions are also included, with more and more cases of
MDRO among patients coming from the community.
Clinicians are, therefore, concerned by these difficult-to-
treat respiratory infections, as the available antimicro-
bials are actually often ineffective. In recent years, re-
searchers have aimed at developing new molecules, in
order to avoid present resistances. There are great ex-
pectations regarding novel antibiotics, and studies are
awaited to prove their efficacy in community acquired
respiratory infections.
Unfortunately, as the majority of novel antibiotics are
under development in phases I and II and some in trial
phase III, clinicians can currently only count on available
molecules. This has originated the search for adjunctive
therapies in CAP patients, which can enhance the effect of
antibiotics and adjuvate immune response. These molecules
could be an alternative strategy to implement the efficacy
of standard CAP treatments.
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